Quite a lot has changed since my last update on GenMark (GNMK)
back in January. COVID-19 has swept around the globe, leading to huge
disruptions in people’s lives as governments try to cope with and limit
the spread of the disease. It has also left the medical community
scrambling for options, including testing options as the U.S. was
unprepared (or at least under-prepared) for the outbreak here.
I
had thought that COVID-19 could provide a boost to GenMark, and the
company has actually seen a bigger lift than I expected. A key unknown
now, though, is whether SARS-CoV-2/COVID-19 quickly fades into part of
our baseline annual experience (particularly if there’s a vaccine) or
whether it remains a significant driver for longer. While GenMark shares
could still have some upside from here, particularly if COVID-19 proves
to be a more persistent issue, I’d be careful about assuming that this
is a “this changes everything” moment.
Read more here:
COVID-19 Bringing Positive Attention To GenMark Diagnostics... For Now
No comments:
Post a Comment